UNSPSC 51333105: Asenapine

This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JKZ19V908O. European Medicines Agency schedules Asenapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30497. Asenapine generally arises in the molecular formula C17H16CLNO. The term ASENAPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, no. 2, 2003, list 49.) Most nations schedule asenapine under HS 29349990 and SITC 51579.

As of Q4 2014, ASENAPINE remains the US FDA Preferred Term for this commodity. Asenapine bears US NLM identifiers UMLS ID C2000088 and NCI Concept Code C72705. SMILES: CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24.

UNSPSC 51333105 Asenapine, a Commodity code, does not align with the actual work state and local governments are currently soliciting under this classification. The recent opportunities tagged to this code involve naloxone procurement, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceuticals and over-the-counter products — none of which involve asenapine, an atypical antipsychotic medication used in psychiatric treatment. The mismatch suggests either a tagging error in the underlying procurement records or a code assignment that does not reflect current purchasing activity.

State and local issuing bodies posting opportunities under this code include Seminole County, Florida (a county health authority), the Texas Health and Human Services Commission (a state agency), and the Minnesota Multistate Cooperative Purchasing Alliance (a state purchasing cooperative serving multiple jurisdictions including Oregon). Recent activity spans Florida, Texas, and Minnesota-Oregon corridor. A representative opportunity is Seminole County's IFB60459723LAS, posted June 30, 2026, with a July 26, 2023 response deadline, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding for quarterly delivery to the Seminole County Community Health Building in Sanford, Florida. The Texas HHS Commission posted an exploratory RFI on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota cooperative issued an RFP on January 20, 2026 (due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed across state and local facilities, with authorized wholesaler relationships and a July 1, 2026 effective date. Because the code's nominal scope and the actual solicitations diverge significantly, business development professionals should verify the correct code assignment before pursuing opportunities tagged here.